Trisalus Life Sciences, INC 10-K annual reports

TriSalus Life Sciences, Inc. reported a 53.4% increase in TriNav revenue for 2025, alongside continued development of its immuno-oncology therapeutic, nelitolimod, while navigating ongoing operating losses and internal control weaknesses.

TriSalus Life Sciences, an oncology-focused medical technology company, reported a significant reduction in net loss and strong revenue growth for the fiscal year ended December 31, 2024, but disclosed substantial doubt about its ability to continue as a going concern due to recurring losses and insufficient liquidity without further financing.

TriSalus Life Sciences reports a 59% increase in revenue for 2024, driven by its TriNav Infusion System, while continuing to develop its immunotherapeutic, nelitolimod.

TriSalus Life Sciences, Inc. reports progress in its innovative oncology platform, combining drug delivery technology with immunotherapy for liver and pancreatic cancers, while facing financial challenges and navigating a complex regulatory environment.